Additional info:
“Histotripsy is FDA-approved for the treatment of primary and metastatic liver tumors, with marketing authorization granted to the Edison histotripsy system by HistoSonics in October 2023. This approval, achieved through the De Novo Classification Request process, marks the first time histotripsy has received regulatory clearance worldwide, allowing it to be used as a non-invasive alternative to surgery, radiation, and chemotherapy for liver cancer.”
Hmmm...well that’s interesting. Also of interest is that the insurer is UnitedHealth Care...